Risk Stratification and Treatment in Smoldering Multiple Myeloma.
| cam.issuedOnline | 2021-12-31 | |
| dc.contributor.author | Lussier, Tyler | |
| dc.contributor.author | Schoebe, Natalie | |
| dc.contributor.author | Mai, Sabine | |
| dc.contributor.orcid | Schoebe, Natalie [0000-0001-7417-3025] | |
| dc.contributor.orcid | Mai, Sabine [0000-0002-5797-2201] | |
| dc.date.accessioned | 2022-01-10T12:45:15Z | |
| dc.date.available | 2022-01-10T12:45:15Z | |
| dc.date.issued | 2021-12-31 | |
| dc.date.updated | 2022-01-10T12:45:14Z | |
| dc.description.abstract | Smoldering multiple myeloma is a heterogeneous asymptomatic precursor to multiple myeloma. Since its identification in 1980, risk stratification models have been developed using two main stratification methods: clinical measurement-based and genetics-based. Clinical measurement models can be subdivided in three types: baseline measurements (performed at diagnosis), evolving measurements (performed over time during follow-up appointments), and imaging (for example, magnetic resonance imaging). Genetic approaches include gene expression profiling, DNA/RNA sequencing, and cytogenetics. It is important to accurately distinguish patients with indolent disease from those with aggressive disease, as clinical trials have shown that patients designated as "high-risk of progression" have improved outcomes when treated early. The risk stratification models, and clinical trials are discussed in this review. | |
| dc.identifier.doi | 10.17863/CAM.79930 | |
| dc.identifier.eissn | 2073-4409 | |
| dc.identifier.issn | 2073-4409 | |
| dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/332480 | |
| dc.language | en | |
| dc.language.iso | eng | |
| dc.publisher | MDPI AG | |
| dc.publisher.url | http://dx.doi.org/10.3390/cells11010130 | |
| dc.subject | risk stratification | |
| dc.subject | smoldering multiple myeloma | |
| dc.subject | treatment | |
| dc.subject | Clinical Trials as Topic | |
| dc.subject | Cytogenetics | |
| dc.subject | DNA | |
| dc.subject | Humans | |
| dc.subject | RNA | |
| dc.subject | Risk Assessment | |
| dc.subject | Risk Factors | |
| dc.subject | Smoldering Multiple Myeloma | |
| dc.title | Risk Stratification and Treatment in Smoldering Multiple Myeloma. | |
| dc.type | Article | |
| dcterms.dateAccepted | 2021-12-28 | |
| prism.issueIdentifier | 1 | |
| prism.publicationName | Cells | |
| prism.volume | 11 | |
| rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0/ | |
| rioxxterms.version | VoR | |
| rioxxterms.versionofrecord | 10.3390/cells11010130 |
Files
Original bundle
1 - 3 of 3
No Thumbnail Available
- Name:
- cells-11-00130.xml
- Size:
- 6.12 KB
- Format:
- Extensible Markup Language
- Description:
- Bibliographic metadata
- Licence
- https://creativecommons.org/licenses/by/4.0/
No Thumbnail Available
- Name:
- additional-files.zip
- Size:
- 102.53 KB
- Format:
- ZIP file
- Description:
- Supporting information
- Licence
- https://creativecommons.org/licenses/by/4.0/
Loading...
- Name:
- cells-11-00130.pdf
- Size:
- 745.3 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version
- Licence
- https://creativecommons.org/licenses/by/4.0/